First-in-Class Innovation for Pain Treatment
Sponsored by: GlobalData
Date: 14 May
Time: 3PM London/10AM New York
An Assessment of Innovation in the Pain Pipeline
Innovation in the pain market over the last decade has been limited to new drug delivery systems, extended-release formulations, and the repositioning of anticonvulsant and antidepressant therapeutics; however the pain market still has significant unmet needs. These include effective alternatives for opioids, which have a high abuse potential, and for therapeutics that provide adequate relief for chronic pain types.
An improved understanding of neuroanatomy has highlighted the distinct pathophysiology of different pain types, which has allowed for the discovery of new molecular targets, in which the action aligns closely to the pathological underpinnings of the specific pain type. This increased understanding has presented attractive opportunities for first-in-class products by offering a wide-range of molecular targets with disease-modifying potential.
In this webinar Mark Needham, Associate Analyst at GlobalData, will present an analysis of the overall pain pipeline with an emphasis on the first-in-class innovation, by drawing on insights from GlobalData’s recently published report, Frontier Pharma: Pain - GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential In Difficult-To-Treat Subtypes. An analysis of the 104 first-in-class molecular targets for pain will be provided as well as a description of how we rank first-in-class targets to determine the most promising. Some of the highest ranking molecular targets will be profiled in detail. Maura Musciacco, Therapy Senior Director at GlobalData, will moderate a Q&A session following the presentation.
Healthcare Associate Analyst
Mark Needham, MChem, is an Associate Analyst at GlobalData in Manchester. Prior to his current role, he was an analyst at GBI Research for over two years and gained experience producing therapy area wide reports in the fields of respiratory disease, genetic disorders, cancer vaccines, hematological cancers and immuno-oncology. He has a MChem in Chemistry from Loughborough University.
Senior Director, Neurology & Ophthalmology
Maura Musciacco, MSc, is the Senior Director of Neurology and Ophthalmology at GlobalData in London. She has over a decade of experience in market analysis, business intelligence and providing strategic insight for the pharmaceutical industry. Prior to her current role, she was a Lead Analyst for Company Analysis at Datamonitor Healthcare, where she managed the portfolio and production of the team covering the top 40 pharmaceutical companies, in addition to being the in-house specialist for the orphan drug sector. Previously, she was an Analyst in the Strategy team at Datamonitor Healthcare, where she gained extensive experience writing in-depth reports covering various topics, including mergers and acquisitions, emerging markets, generics, and R&D trends. Maura started her career in market research, where she uncovered needs and trends in several therapeutic markets. She has an MSc in International Health Management from the Imperial College Business School, and a BSc in Molecular Biology from University College London (UCL).
Key Learning Objectives
- Learn how GlobalData has assessed the degree of first-in-class innovation in the pain pipeline
- Gain insight into which first-in-class drug targets GlobalData deems to be the most promising for pain
- Assess the pain pipeline by stage of development, molecule type and molecular target
- Learn which companies are the most active in developing first-in-class pain products
- Senior Managers
- Associate Directors
- Directors of Market Research
- Business Insights
- Market Intelligence
- Strategic Insights
- Pipeline Management
- Competitive Strategy
- Customer Insights
- Heads of Research and Development
- Heads of Product Planning and Marketing
- Brand Managers